{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:06:53Z","timestamp":1790968013213,"version":"4.1.0"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"<jats:p>This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with surrogate outcomes that did not demonstrate net benefits.<\/jats:p>","DOI":"10.1001\/jama.2024.5613","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:11:02Z","timestamp":1714576262000},"page":"1705","source":"Crossref","is-referenced-by-count":24,"title":["The FDA and Gene Therapy for Duchenne Muscular Dystrophy"],"prefix":"10.1001","volume":"331","author":[{"given":"David M.","family":"Rind","sequence":"first","affiliation":[{"name":"Institute for Clinical and Economic Review, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"jvp240036r1","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.7326\/M23-1073","article-title":"The regulatory repercussions of approving muscular dystrophy medications on the basis of limited evidence.","volume":"176","author":"Bendicksen","year":"2023","journal-title":"Ann Intern Med"},{"issue":"4","key":"jvp240036r2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.18553\/jmcp.2020.26.4.361","article-title":"The effectiveness and value of deflazacort and exon-skipping therapies for the management of Duchenne muscular dystrophy.","volume":"26","author":"Agboola","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"jvp240036r3","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/biom13101536","article-title":"Pharmacotherapeutic approaches to treatment of muscular dystrophies.","volume":"13","author":"Rawls","year":"2023","journal-title":"Biomolecules"},{"issue":"5","key":"jvp240036r4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/WCO.0000000000001191","article-title":"An update on Becker muscular dystrophy.","volume":"36","author":"Straub","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"jvp240036r7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"jvp240036r8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.18553\/jmcp.2024.30.2.201","article-title":"Atidarsagene autotemcel for metachromatic leukodystrophy.","volume":"30","author":"Fahim","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"jvp240036r5","unstructured":"US Food and Drug Administration. BLA# 125781\/00. Published May 12, 2023. Accessed February 15, 2024. https:\/\/www.fda.gov\/media\/168021\/download"},{"key":"jvp240036r6","unstructured":"Sarepta Therapeutics announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. News release. Published October 30, 2023. Accessed February 15, 2024. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-topline-results-embark-global-0"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2818205\/jama_rind_2024_vp_240036_1716416449.7156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T18:03:53Z","timestamp":1716919433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2818205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":8,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.5613","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}